<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043808</url>
  </required_header>
  <id_info>
    <org_study_id>1160.183</org_study_id>
    <nct_id>NCT02043808</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage</brief_title>
  <official_title>The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective is to assess the safety and effectiveness of new dabigatran and warfarin
      patients diagnosed with NVAF in the US DoD population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      Retrospective
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke (Hemorrhagic, Ischemic)</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period)</time_frame>
    <description>Event rate of stroke (hemorrhagic, ischemic).
Variables in the final propensity score model: age, gender index year, baseline CHADS(2) score (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Prior Stroke or transient ischemic attack (TIA) or Thromboembolism), baseline CHA(2)DS(2)-VASc score (Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Stroke (doubled), Vascular disease, Age 65-74 years, Sex category), baseline HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio, Elderly, Drugs/alcohol concomitantly), baseline use of several medications and presence of several baseline co-morbidities.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period)</time_frame>
    <description>Event rate of major bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic Stroke</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period)</time_frame>
    <description>Event rate of ischemic stroke.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic Stroke</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of hemorrhagic stroke.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Intracranial Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major intracranial bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Extracranial Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major extracranial bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major GI Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Upper GI Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major upper gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Lower GI Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major lower gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Urogenital Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major urogenital bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Other Bleeding</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of major other bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attack</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of transient ischemic attacks.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of myocardial infarction.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of venous thromboembolism.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of deep vein thrombosis.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of pulmonary embolism.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
    <description>Event rate of death, due to any cause.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25586</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        NVAF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients must be continuously enrolled in a health plan during the pre-index period;

          -  Patients must have at least one inpatient, or one physician office visit, emergency
             room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on
             the index date or during the pre-index period;

          -  Patients must have a prescription for dabigatran or warfarin (this first prescription
             will be the index date);

          -  Patients must be treatment naive from all OAC use prior to first dabigatran or
             warfarin prescription;

          -  Aged 18-89 on the index date;

        Exclusion criteria:

          -  Patients with valvular procedures related to the baseline AF diagnosis will be
             excluded;

          -  Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery,
             pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first
             diagnosis of AF;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.183.01 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>May 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2015</results_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Existing data cohort design with propensity score matching (PSM). Variables included in the final propensity score model were: age, gender index year, baseline CHADS(2) score, baseline CHA(2)DS(2)-VASc score, baseline HAS-BLED score, baseline use of several medications and presence of several baseline co-morbidities.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12793"/>
                <participants group_id="P2" count="12793"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12793"/>
                <participants group_id="P2" count="12793"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Post-PSM set</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12793"/>
            <count group_id="B2" value="12793"/>
            <count group_id="B3" value="25586"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.8" spread="9.3"/>
                    <measurement group_id="B2" value="74.0" spread="9.0"/>
                    <measurement group_id="B3" value="73.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5277"/>
                    <measurement group_id="B2" value="5253"/>
                    <measurement group_id="B3" value="10530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7516"/>
                    <measurement group_id="B2" value="7540"/>
                    <measurement group_id="B3" value="15056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stroke (Hemorrhagic, Ischemic)</title>
        <description>Event rate of stroke (hemorrhagic, ischemic).
Variables in the final propensity score model: age, gender index year, baseline CHADS(2) score (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Prior Stroke or transient ischemic attack (TIA) or Thromboembolism), baseline CHA(2)DS(2)-VASc score (Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Stroke (doubled), Vascular disease, Age 65–74 years, Sex category), baseline HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio, Elderly, Drugs/alcohol concomitantly), baseline use of several medications and presence of several baseline co-morbidities.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period)</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke (Hemorrhagic, Ischemic)</title>
          <description>Event rate of stroke (hemorrhagic, ischemic).
Variables in the final propensity score model: age, gender index year, baseline CHADS(2) score (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Prior Stroke or transient ischemic attack (TIA) or Thromboembolism), baseline CHA(2)DS(2)-VASc score (Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Stroke (doubled), Vascular disease, Age 65–74 years, Sex category), baseline HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio, Elderly, Drugs/alcohol concomitantly), baseline use of several medications and presence of several baseline co-morbidities.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.15" lower_limit="7.41" upper_limit="11.19"/>
                    <measurement group_id="O2" value="13.19" lower_limit="10.74" upper_limit="16.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Bleeding</title>
        <description>Event rate of major bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period)</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>Event rate of major bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.84" lower_limit="27.55" upper_limit="34.42"/>
                    <measurement group_id="O2" value="37.04" lower_limit="32.82" upper_limit="41.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemic Stroke</title>
        <description>Event rate of ischemic stroke.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period)</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemic Stroke</title>
          <description>Event rate of ischemic stroke.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.48" lower_limit="6.80" upper_limit="10.45"/>
                    <measurement group_id="O2" value="10.69" lower_limit="8.49" upper_limit="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemorrhagic Stroke</title>
        <description>Event rate of hemorrhagic stroke.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Hemorrhagic Stroke</title>
          <description>Event rate of hemorrhagic stroke.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.33" upper_limit="1.51"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.50" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Intracranial Bleeding</title>
        <description>Event rate of major intracranial bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Intracranial Bleeding</title>
          <description>Event rate of major intracranial bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" lower_limit="1.79" upper_limit="3.88"/>
                    <measurement group_id="O2" value="5.65" lower_limit="4.09" upper_limit="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Extracranial Bleeding</title>
        <description>Event rate of major extracranial bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Extracranial Bleeding</title>
          <description>Event rate of major extracranial bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.13" lower_limit="24.99" upper_limit="31.55"/>
                    <measurement group_id="O2" value="31.30" lower_limit="27.44" upper_limit="35.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major GI Bleeding</title>
        <description>Event rate of major gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major GI Bleeding</title>
          <description>Event rate of major gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.40" lower_limit="22.42" upper_limit="28.66"/>
                    <measurement group_id="O2" value="23.69" lower_limit="20.34" upper_limit="27.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Upper GI Bleeding</title>
        <description>Event rate of major upper gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Upper GI Bleeding</title>
          <description>Event rate of major upper gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="4.15" upper_limit="7.10"/>
                    <measurement group_id="O2" value="7.63" lower_limit="5.80" upper_limit="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Lower GI Bleeding</title>
        <description>Event rate of major lower gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Lower GI Bleeding</title>
          <description>Event rate of major lower gastrointestinal (GI) bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.25" lower_limit="17.60" upper_limit="23.18"/>
                    <measurement group_id="O2" value="16.38" lower_limit="13.62" upper_limit="19.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Urogenital Bleeding</title>
        <description>Event rate of major urogenital bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Urogenital Bleeding</title>
          <description>Event rate of major urogenital bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.53" upper_limit="1.89"/>
                    <measurement group_id="O2" value="3.02" lower_limit="1.92" upper_limit="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Other Bleeding</title>
        <description>Event rate of major other bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Major Other Bleeding</title>
          <description>Event rate of major other bleeding.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.17" upper_limit="2.97"/>
                    <measurement group_id="O2" value="5.13" lower_limit="3.65" upper_limit="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transient Ischemic Attack</title>
        <description>Event rate of transient ischemic attacks.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Transient Ischemic Attack</title>
          <description>Event rate of transient ischemic attacks.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="3.40" upper_limit="6.12"/>
                    <measurement group_id="O2" value="5.53" lower_limit="3.99" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>Event rate of myocardial infarction.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>Event rate of myocardial infarction.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" lower_limit="3.82" upper_limit="6.66"/>
                    <measurement group_id="O2" value="7.77" lower_limit="5.92" upper_limit="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Thromboembolism</title>
        <description>Event rate of venous thromboembolism.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Thromboembolism</title>
          <description>Event rate of venous thromboembolism.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="0.73" upper_limit="2.25"/>
                    <measurement group_id="O2" value="2.10" lower_limit="1.20" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deep Vein Thrombosis</title>
        <description>Event rate of deep vein thrombosis.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Deep Vein Thrombosis</title>
          <description>Event rate of deep vein thrombosis.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.21" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0.63" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Embolism</title>
        <description>Event rate of pulmonary embolism.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Embolism</title>
          <description>Event rate of pulmonary embolism.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.33" upper_limit="1.51"/>
                    <measurement group_id="O2" value="0.79" lower_limit="0.29" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Event rate of death, due to any cause.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
        <time_frame>From October 1, 2009 through July 31, 2013 (the study period).</time_frame>
        <population>All patients in the post-propensity score matching cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Event rate of death, due to any cause.
The 12-month period prior to and including the index date was defined as the baseline period. Patients were required to have an NVAF diagnosis during this baseline period.</description>
          <population>All patients in the post-propensity score matching cohort</population>
          <units>Events per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12793"/>
                <count group_id="O2" value="12793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.28" lower_limit="27.98" upper_limit="34.87"/>
                    <measurement group_id="O2" value="52.41" lower_limit="47.40" upper_limit="57.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude event rate ratio</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
            <estimate_desc>Crude event rate ratio for dabigatran with warfarin as the reference group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective observational study, therefore all patient data was de-identified and analysed in aggregate. Thus, individual patient data is not available and reporting of adverse events is not applicable.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for dabigatran (either FDA-approved dose) during the study identification period (1 October 2010 and 31 July 2012).</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Oral anticoagulant treatment-naive non-valvular atrial fibrillation (NVAF) patients aged 18-89 with their first prescription claim for warfarin during the study identification period (1 October 2010 and 31 July 2012).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

